EP Patent

EP3725777A1 — Benzo- and pyrido-pyrazoles as protein kinase inhibitors

Assigned to Rottapharm Biotech SRL · Expires 2020-10-21 · 6y expired

What this patent protects

The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.

USPTO Abstract

The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.

Drugs covered by this patent

Patent Metadata

Patent number
EP3725777A1
Jurisdiction
EP
Classification
—
Expires
2020-10-21
Drug substance claim
No
Drug product claim
No
Assignee
Rottapharm Biotech SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.